Its use in weight management, metabolic syndrome, and diabetes
Alpha-lipoic acid (ALA), also known simply as lipoic acid, is a naturally-occurring substance that is an essential cofactor for several enzymes. ALA, synthesized in the body from a medium-chain fatty acid known as octanoic acid, plays a key role in mitochondrial metabolism and energy production.,
ALA is also a potent antioxidant with anti-inflammatory activity. It neutralizes reactive oxygen and nitrogen species, and helps regenerate the active forms of vitamin E, coenzyme Q10, and glutathione.,,, ALA is one of several nutrients that support the nuclear factor E2-related factor 2 (Nrf2) pathway, a master regulator of antioxidant defenses, including glutathione.,
Some foods contain ALA, including organ meats, red meat, spinach, broccoli, and tomatoes. However, because dietary ALA is bound to proteins, the consumption of high-ALA foods does not increase free ALA in human plasma or cells., By contrast, oral supplementation with ALA has been shown to significantly increase the concentration of free ALA in the body.,
Multiple studies now show that ALA helps maintain healthy body weight and blood glucose levels, which may reduce the risk of type 2 diabetes (T2DM) and attenuate its effects. We’ll touch on each of these key findings in this article.
Effect of lipoic acid on metabolic syndrome and diabetes
Metabolic syndrome is a condition associated with abdominal obesity, increased blood pressure, high cholesterol and/or triglycerides, inflammation, insulin resistance or full-blown diabetes, and a heightened risk of cardiovascular disease. Obesity is the major determinant of metabolic syndrome, both of which are all-too-common clinical and public health challenges.
Insulin resistance is typified by a reduced cellular sensitivity to the signaling molecule insulin, which leads to decreased cellular uptake and utilization of glucose in response to insulin binding receptors on the cell membrane. Because of the reduced sensitivity to insulin, the body simply increases insulin production to try to overcome this problem. With time, insulin resistance leads to elevated blood glucose levels (hyperglycemia), which causes oxidative stress and ultimately damages the heart, nerves, blood vessels, and many organs. Antioxidants that can enhance insulin sensitivity and reduce oxidative stress are of great interest, as they may protect against the damaging effects of hyperglycemia. Laboratory, animal, and human studies suggest that ALA has these important properties.,
In laboratory studies, ALA was shown to increase glucose uptake in adipose and muscle cells., In animal models of metabolic syndrome or T2DM, the administration of ALA attenuated insulin resistance.,,, In animals, ALA also reduces the metabolic effects of high-fructose diets, which are known to contribute to obesity and T2DM., (Fructose is a component of sucrose, a major contributor to the obesity epidemic.)
Numerous clinical trials have shown that oral supplementation with ALA improves insulin sensitivity in individuals with T2DM.,, A 2018 systematic review of 20 randomized controlled trials, involving over 1000 subjects with metabolic disorders (not limited to T2DM), showed that the administration of lipoic acid (200 to 1800 mg per day, for two weeks to one year) helped lower fasting blood glucose and insulin concentrations, insulin resistance, and blood hemoglobin A1c (HbA1c) levels, a marker of long-term glycemic control. In various studies, ALA supplementation also lowered serum total cholesterol and low density lipoprotein (LDL)-cholesterol levels, which are risk factors for cardiovascular disease.
ALA not only helps regulate blood glucose and cholesterol, but it may directly impact obesity, which is a major contributor to diabetes, cancer, and cardiovascular disease.
ALA not only helps regulate blood glucose and cholesterol, but it may directly impact obesity, which is a major contributor to diabetes, cancer, and cardiovascular disease. Multiple randomized, placebo-controlled trials have found that ALA supplementation in individuals with high body mass index (BMI) produced a modest but significant reduction in body weight compared to placebo.,,, Other clinical studies suggest that ALA supports cardiovascular health in overweight or obese individuals.,
Effects of lipoic acid on peripheral neuropathy
Up to 50% of diabetic patients develop peripheral neuropathy (PN), a type of nerve damage associated with pain, loss of sensation, and weakness in the lower extremities. Oxidative stress is one of the main contributors to the development of PN., Due to its antioxidant properties, ALA has been studied as a supplement to potentially reduce the risk of PN.,
In laboratory studies, ALA was shown to attenuate the neurotoxicity induced by high glucose levels, improve nerve conduction parameters, and promote nerve fiber regeneration., In an animal model of PN, ALA improved glucose uptake into nerves, and increased the velocity and amplitude of the signal conducted through them. A combination of ALA and coenzyme Q10, both of which are mitochondrial antioxidants, was particularly effective in animal studies.
In human clinical trials, ALA also has been shown to reduce the risk and/or signs of PN.,, In medically-supervised trials, in which ALA is often administered by intravenous infusion, diabetic patients with PN experienced a reduction in pain, paresthesia (burning or prickling sensation), and numbness after several weeks of ALA treatment., A meta-analysis of 20 randomized controlled trials concludes that ALA may be useful as an adjunct to common drug treatments for PN.
At a dosage of only 600 mg per day (taken for 40 days), ALA was shown to lead to symptom ratings of ‘very much better’ or ‘much better’ in half of all participants.
Several studies also suggest that oral supplementation of ALA may help improve PN.,, In one clinical trial, 45 patients with T2DM and PN were supplemented with ALA (600 mg orally three times daily) for four weeks. During this phase of the trial, ALA reduced the total symptom score (TSS) by 61% on average. The responders were then randomized to receive ALA (600 mg once daily) or to ALA withdrawal for 16 weeks. TSS was further reduced by 32% in those who continued on ALA, and the use of analgesics for neuropathic pain was 50% lower in the ALA group compared with the withdrawal group. In a 2018 study of patients with painful diabetic neuropathy, at a dosage of only 600 mg per day (taken for 40 days), ALA was shown to lead to symptom ratings of ‘very much better’ or ‘much better’ in half of all participants.
One clinical trial with 181 diabetic individuals with PN showed that ALA supplementation (either 600, 1200, or 1800 mg per day for five weeks) significantly improved neuropathic symptoms and quality of life.57 The 600 mg/day dose was as effective as the higher doses. However, another placebo-controlled study by the same researchers found no effect of ALA on the total neuropathy score after four years. Post-hoc analysis of these data revealed that the long-term efficacy of ALA depends on individual patient characteristics. Somewhat surprisingly, those having a longer duration of diabetes and peripheral neuropathy were more responsive to ALA.
In an outpatient study, 443 diabetic patients with PN were supplemented with 600 mg of ALA daily for a mean period of five years. They were then withdrawn from ALA altogether, or switched to a common medication used for nerve pain. In the group withdrawn from ALA, 73% of the patients developed neuropathic symptoms, which began as soon as two weeks after ALA was discontinued. These results suggest that ALA is a useful supplemental option for individuals with PN, with the impact becoming even more apparent when the supplement was withdrawn. Interestingly, in the group that switched from ALA to the analgesic drug, 45% of the patients had to stop taking the drug due to its side effects. This compares to the side effect rate of only 3% in patients receiving ALA, with side effects being mainly nausea and postprandial fullness.
A 2018 review article concludes, “Studies analyzing the effects of ALA have shown significant reduction of neuropathy symptoms in diabetic patients. In addition, ALA exhibits activity in weight management and insulin sensitivity.” And: “Current data provides evidence for the benefits of lipoic acid at a dose of 600 mg per day, either intravenously or orally, for a duration of at least 3 weeks with minimal side effects.”
“Lipoic acid supplementation is an achievable adjunct therapy to help prevent vision loss in diabetic patients.”
Finally, various studies suggest that ALA supplementation may be beneficial for individuals with diabetic retinopathy,,, a serious condition that can impair vision. A recent review article states, “Lipoic acid supplementation is an achievable adjunct therapy to help prevent vision loss in diabetic patients.”
Lipoic acid is an important player in an armamentarium of natural approaches that can assist in the management of metabolic syndrome and/or diabetes. Since taking lipoic acid with food can potentially decrease its bioavailability, it is generally recommended that lipoic acid be taken 30 minutes before or two hours after eating. As always, individuals with signs or symptoms of metabolic syndrome or diabetes should seek care from a qualified health professional when taking a supplement that can potentially impact blood glucose, insulin, and other markers.
For more information on natural approaches to metabolic syndrome and diabetes, also see:
Beating Metabolic Syndrome Before It Beats You
Banaba’s Powerful Effects in Diabetes
Defeating Diabetes: Keeping Your Sugars in Check through the Holidays
 Solmonson A, DeBerardinis RJ. Lipoic acid metabolism and mitochondrial redox regulation. J Biol Chem. 2018 May 18;293(20):7522-30.
 Cronan JE. Assembly of lipoic acid on its cognate enzymes: an extraordinary and essential biosynthetic pathway. Microbiol Mol Biol Rev. 2016 Apr 13;80(2):429-50.
 Reed LJ. From lipoic acid to multi-enzyme complexes. Protein Sci. 1998 Jan;7(1):220-4.
 Reed LJ. A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes. J Biol Chem. 2001 Oct 19;276(42):38329-36.
 Bast A, Haenen GR. Lipoic acid: a multifunctional antioxidant. Biofactors. 2003;17(1-4):207-13.
 Kozlov AV, et al. Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch Biochem Biophys. 1999 Mar 1;363(1):148-54.
 Busse E, et al. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung. 1992 Jun;42(6):829-31.
 Han D, et al. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors. 1997;6(3):321-38.
 Jones W, et al. Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radic Biol Med. 2002 Jul 1;33(1):83-93.
 Suh JH, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3381-6.
 Zhang J, et al. Regeneration of glutathione by α-lipoic acid via Nrf2/ARE signaling pathway alleviates cadmium-induced HepG2 cell toxicity. Environ Toxicol Pharmacol. 2017 Apr;51:30-7.
 Lodge JK, et al. Natural sources of lipoic acid: determination of lipoyllysine released from protease-digested tissues by high performance liquid chromatography incorporating electrochemical detection. J Appl Nutr. 1997 Dec 1;49(1-2):3-11.
 Smith AR, et al. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 2004 May;11(9):1135-46.
 Hermann R, et al. Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. Eur J Pharm Sci. 1996 May 1;4(3):167-74.
 Teichert J, et al. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol. 2003 Nov;43(11):1257-67.
 Breithaupt-Grögler K, et al. Dose-proportionality of oral thioctic acid–coincidence of assessments via pooled plasma and individual data. Eur J Pharm Sci. 1999 Apr;8(1):57-65.
 Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006 Dec 14;444(7121):881-7.
 Sherling DH, et al. Metabolic syndrome. J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):365-7.
 Román-Pintos LM, et al. Diabetic polyneuropathy in type 2 diabetes mellitus: inflammation, oxidative stress, and mitochondrial function. J Diabetes Res. 2016;2016:3425617.
 Estrada DE, et al. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Diabetes. 1996 Dec;45(12):1798-804.
 Saengsirisuwan V, et al. Interactions of exercise training and alpha-lipoic acid on insulin signaling in skeletal muscle of obese Zucker rats. Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E529-36.
 Yaworsky K, et al. Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes. Diabetologia. 2000 Mar;43(3):294-303.
 Yang Y, et al. Alpha-lipoic acid attenuates insulin resistance and improves glucose metabolism in high fat diet-fed mice. Acta Pharmacol Sin. 2014 Oct;35(10):1285-92.
 Castro MC, et al. Fructose-induced inflammation, insulin resistance and oxidative stress: a liver pathological triad effectively disrupted by lipoic acid. Life Sci. 2015 Sep 15;137:1-6.
 Lee WJ, et al. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005 Jul 8;332(3):885-91.
 Sena CM, et al. Lipoic acid prevents high-fat diet-induced hepatic steatosis in Goto Kakizaki rats by reducing oxidative stress through Nrf2 activation. Int J Mol Sci. 2018 Sep 11;19(9):2706.
 Cummings BP, et al. Dietary fructose accelerates the development of diabetes in UCD-T2DM rats: amelioration by the antioxidant, alpha-lipoic acid. Am J Physiol Regul Integr Comp Physiol. 2010 May;298(5):R1343-50.
 Castro MC, et al. Alpha-lipoic acid and its protective role in fructose induced endocrine-metabolic disturbances. Food Funct. 2019 Jan 22;10(1):16-25.
 Johnson RJ, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007 Oct;86(4):899-906.
 Jacob S, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999 Aug;27(3-4):309-14.
 Ansar H, et al. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Med J. 2011 Jun;32(6):584-8.
 Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens). 2006 Oct-Dec;5(4):251-8.
 Akbari M, et al. The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Metabolism. 2018 Oct;87:56-69.
 Haghighatdoost F, Hariri M. Does alpha-lipoic acid affect lipid profile? A meta-analysis and systematic review on randomized controlled trials. Eur J Pharmacol. 2019 Mar 15;847:1-10.
 Guh DP, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009 Mar 25;9:88.
 Namazi N, et al. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2018 Apr;37(2):419-28.
 Kucukgoncu S, et al. Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obes Rev. 2017 May;18(5):594-601.
 Koh EH, et al. Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med. 2011 Jan;124(1):85.
 Li N, et al. Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2017 May;86(5):680-7.
 Tromba L, et al. Effect of alpha-lipoic acid supplementation on endothelial function and cardiovascular risk factors in overweight/obese youths: a double-blind, placebo-controlled randomized trial. Nutrients. 2019 Feb 12;11(2):375.
 Huerta AE, et al. Supplementation with α-lipoic acid alone or in combination with eicosapentaenoic acid modulates the inflammatory status of healthy overweight or obese women consuming an energy-restricted diet. J Nutr. 2015 Apr 1;146(4):889S-96S.
 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetic neuropathy [Internet]. Bethesda (MD): National Institutes of Health; 2018 [cited 2019 Aug 18]. Available at: https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies
 Obrosova IG. Diabetes and the peripheral nerve. Biochim Biophys Acta. 2009 Oct;1792(10):931-40.
 Greene DA, et al. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol. 1999 Jun 30;375(1-3):217-23.
 Tasci I, et al. Effects of alpha lipoic acid on loss of myelin sheath of sciatic nerve in experimentally induced diabetic rats. Med Arch. 2018 Jun;72(3):178-81.
 Han Y, et al. Differential efficacy of methylcobalamin and alpha-lipoic acid treatment on symptoms of diabetic peripheral neuropathy. Minerva Endocrinol. 2018 Mar;43(1):11-8.
 Najafi R, et al. Protective effects of alpha lipoic acid on high glucose-induced neurotoxicity in PC12 cells. Metab Brain Dis. 2015 Jun;30(3):731-8.
 Dimpfel W, et al. Thioctic acid induces dose-dependent sprouting of neurites in cultured rat neuroblastoma cells. Dev Pharmacol Ther. 1990;14(3):193-9.
 Kishi Y, et al. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes. 1999 oct;48(10):2045-51.
 Seyit DA, et al. Evaluation of electrophysiological effects of melatonin and alpha lipoic acid in rats with streptozotocine induced diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2016 May;124(5):300-6.
 Sadeghiyan Galeshkalami N, et al. Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis. Life Sci. 2019 Jan 1;216:101-110.
 Vallianou N, et al. Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud. 2009 Winter;6(4):230-6.
 Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol. 2004;3(3):173-89.
 Han T, et al. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012 Oct;167(4):465-71.
 Ametov AS, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 Mar;26(3):770-6.
 Zhao M, et al. Efficacy of epalrestat plus α-lipoic acid combination therapy versus monotherapy in patients with diabetic peripheral neuropathy: a meta-analysis of 20 randomized controlled trials. Neural Regen Res. 2018 Jun;13(6):1087-95.
 Ziegler D, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70.
 Wilson S, Sariga P. Role of alpha-lipoic acid in diabetic peripheral neuropathy. Global J Res Anal. 2019 Aug 7;8(3):44-7.
 McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377-85.
 Garcia-Alcala H, et al. Treatment with α-lipoic acid over 16 weeks in type 2 diabetic patients with symptomatic polyneuropathy who responded to initial 4-week high-dose loading. J Diabetes Res. 2015;2015:189857.
 Agathos E, et al. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res. 2018 May;46(5):1779-90.
 Ziegler D, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60.
 Ziegler D, et al. Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial. J Diabetes Complications. 2016 Mar;30(2):350-6.
 Ruessmann HJ, et al. Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. J Diabetes Complications. 2009 May-Jun;23(3):174-7.
 Nguyen N, Takemoto JK. A case for alpha-lipoic acid as an alternative treatment for diabetic polyneuropathy. J Pharm Pharm Sci. 2018;21(1s):177s-91s.
 Gębka A, et al. Effect of the administration of alpha-lipoic acid on contrast sensitivity in patients with type 1 and type 2 diabetes. Mediators Inflamm. 2014;2014:131538.
 Kan E, et al. Effects of alpha-lipoic acid on retinal ganglion cells, retinal thicknesses, and VEGF production in an experimental model of diabetes. Int Ophthalmol. 2017 Dec;37(6):1269-78.
 Johnsen-Soriano S, et al. Early lipoic acid intake protects retina of diabetic mice. Free Radic Res. 2008 Jul;42(7):613-7.
 Nebbioso M, et al. Lipoic acid in animal models and clinical use in diabetic retinopathy. Expert Opin Pharmacother. 2013 Sep;14(13):1829-38.
 Gleiter CH, et al. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol. 1996;50(6):513-4.